A tablet manufacturing process, comprising: compressing a pre-tablet material in a matrix at a pressure greater than or equal to 1 ton / cm 2 to form a tablet, wherein an internal surface of the matrix is lubricated with at least a lubricant, and said pre-tabletting material comprises at least one therapeutic agent and at least one pharmaceutically acceptable polymer； and ejecting said tablet from said matrix, wherein: said pre-tabletting material does not include: (1) any therapeutic agent that is denatured or deactivated when compressed at a pressure greater than or equal to 1 ton / cm2, (2) any active ingredient of a small molecule whose elution is delayed when compressed at a pressure greater than or equal to 1 ton / cm2, or (3) any therapeutic agent that is affected by said at least one lubricant； said pre-tabletting material comprises a solid dispersion of said therapeutic agent in a matrix, and said matrix comprises said pharmaceutically acceptable polymer； said pre-tabletting material comprises at least 30% by weight of said at least one pharmaceutically acceptable polymer； said at least one lubricant comprises sodium stearyl fumarate； and said pre-tabletting material comprises less than 0.2% by weight of lubricant.Un proceso de fabricación de tabletas, que comprende: comprimir un material de pre-tableteado en una matriz a una presión mayor que o igual a 1 ton/cm2 para formar una tableta, en donde una superficie interna de la matriz está lubricada con al menos un lubricante, y dicho material de pre-tableteado comprende al menos un agente terapéutico y al menos un polímero farmacéuticamente aceptable； y eyectar dicha tableta de dicha matriz, en donde: dicho material de pre-tableteado no incluye: (1) agente terapéutico alguno que se desnaturalice o desactive cuando se comprime a una presión mayor que o igual a 1 ton/cm2, (2) ingrediente activo alguno de molécula pequeña cuya elución se retarde cuando se comprime a una presión mayor que o igual a 1 ton/cm2, o (
